Aduro Biotech Inc. (NASDAQ:ADRO)’s share price traded up 2.4% during trading on Tuesday . The stock traded as high as $14.13 and last traded at $14.07, with a volume of 83,568 shares trading hands. The stock had previously closed at $13.74.

Several research firms have recently issued reports on ADRO. FBR & Co reaffirmed a “buy” rating and set a $34.00 price target (up previously from $30.00) on shares of Aduro Biotech in a research note on Saturday, May 14th. Leerink Swann reaffirmed a “buy” rating and set a $48.00 price target on shares of Aduro Biotech in a research note on Thursday, May 5th. Canaccord Genuity reaffirmed a “buy” rating on shares of Aduro Biotech in a research note on Tuesday, May 3rd. Roth Capital reaffirmed a “buy” rating and set a $22.00 price target (down previously from $46.00) on shares of Aduro Biotech in a research note on Monday, May 16th. Finally, Zacks Investment Research downgraded shares of Aduro Biotech from a “hold” rating to a “sell” rating in a research note on Monday, July 18th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $22.00.

The stock’s market capitalization is $903.32 million. The firm has a 50-day moving average price of $14.43 and a 200 day moving average price of $13.22.

Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.18) by $0.21. The firm had revenue of $39 million for the quarter, compared to analysts’ expectations of $25.24 million. The firm’s quarterly revenue was up 306.3% compared to the same quarter last year. On average, analysts expect that Aduro Biotech Inc. will post ($1.39) EPS for the current fiscal year.

In other Aduro Biotech news, insider Thomas W. Dubensky sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $15.18, for a total value of $379,500.00. Following the completion of the transaction, the insider now owns 12,500 shares of the company’s stock, valued at approximately $189,750. The transaction was disclosed in a filing with the SEC, which is available through this link.

Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.